Kyverna Therapeutics Set to Raise $319M with $22 per Share Offering

• Patient-focused biopharmaceutical venture Kyverna Therapeutics (KYTX) has announced the pricing of an enlarged initial public offering of 14.5M shares at an IPO price of $22.00 per share.
• The offering is anticipated to generate gross proceeds of $319M.
• The common stock is projected to debut trading on the Nasdaq Global Select Market on February 8, 2024, utilizing the ticker symbol “KYTX.”
• Subsequently, the offering is expected to conclude on or about February 12, 2024.
• Underwriters are granted a 30-day option to acquire up to approximately 2.18M additional shares.

More on Kyverna Therapeutics

5 Stocks Our Experts Predict Could Double In the Next Year

By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.